Histone methylation plays important roles in regulating gene expression and diverse biological processes [1] . Methylation of a unique residue, lysine 79 of histone H3 (H3K79), is evolutionarily conserved from yeast to human and is catalyzed by yeast Dot1 (disruptor of telomeric silencing) and its mammalian homolog DOT1L (Dot1-Like), respectively [2] . Previous studies have revealed that Dot1/DOT1L and its associated H3K79 methylation mark are involved in various biological processes including transcriptional regulation, DNA repair, and cell cycle regulation [3] . In addition, DOT1L and H3K79 methylation are also important for cardiac function [4] and leukemogenesis [5] [6] [7] . The fact that DOT1L, particularly its enzymatic activity, is involved in multiple MLL-related acute leukemias implies its potential role as a therapeutic target. However, the role of DOT1L in normal hematopoiesis is still unknown. Such information is critical for developing a DOT1L-based therapeutic strategy against acute leukemia. Here we use DOT1L-knockout mice coupled with bone marrow transplantation to demonstrate that DOT1L plays an important role in adult hematopoiesis.
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Histone methylation plays important roles in regulating gene expression and diverse biological processes [1] . Methylation of a unique residue, lysine 79 of histone H3 (H3K79), is evolutionarily conserved from yeast to human and is catalyzed by yeast Dot1 (disruptor of telomeric silencing) and its mammalian homolog DOT1L (Dot1-Like), respectively [2] . Previous studies have revealed that Dot1/DOT1L and its associated H3K79 methylation mark are involved in various biological processes including transcriptional regulation, DNA repair, and cell cycle regulation [3] . In addition, DOT1L and H3K79 methylation are also important for cardiac function [4] and leukemogenesis [5] [6] [7] . The fact that DOT1L, particularly its enzymatic activity, is involved in multiple MLL-related acute leukemias implies its potential role as a therapeutic target. However, the role of DOT1L in normal hematopoiesis is still unknown. Such information is critical for developing a DOT1L-based therapeutic strategy against acute leukemia. Here we use DOT1L-knockout mice coupled with bone marrow transplantation to demonstrate that DOT1L plays an important role in adult hematopoiesis.
Since germ-line DOT1L-knockout mice die before definitive hematopoiesis at embryonic stage [8] , we generated an inducible DOT1L-knockout mouse line to evaluate the role of DOT1L in adult hematopoiesis. To this end, we crossed the DOT1L conditional mice with a Cre-ER mouse line (R26-Cre-ER), so that DOT1L can be deleted in vivo by Tamoxifen (TAM) injection (Supplementary information, Data S1). To examine the role of DOT1L in normal adult hematopoiesis, 8-12-weekold wild-type (DOT1L wt/wt /Cre-ER) and heterozygous (DOT1L 2lox/1ox /Cre-ER) mice were administered TAM every 2 days for a period of 2 weeks. RT-qPCR analysis demonstrated that this regimen of TAM treatment can induce efficient recombination leading to DOT1L depletion (Supplementary information, Figure S1 ). One week after the last injection, the DOT1L 2lox/1ox /Cre-ER mice began to display signs of anemia and bleeding, while the wild- /Cre-ER mice was also observed when compared to wild-type controls ( Figure 1C) .
To determine the effect of DOT1L depletion in hematopoietic lineage development, FACS analyses were performed on bone marrow cells isolated from the experimental mice (Supplementary information, Data S1). The results demonstrated that the percentages of multiple progenitors including CMP (common myeloid progenitors), GMP (granulocyte/monocyte progenitors), and MEP (megakaryocyte/erythrocyte progenitors) are reduced significantly in DOT1L 2lox/1ox /Cre-ER mice compared with the wild-type control ( Figure 1D , Supplementary information, Figure S2 ). Consistently, terminally differentiated myeloid lineage cells (Gr-1+ or Mac-1+) are also significantly reduced upon DOT1L deletion ( Figure  1E , Supplementary information, Figure S2 ). Collectively, these data indicate that DOT1L is critical in maintaining normal adult hematopoiesis and that depletion of DOT1L leads to bone marrow failure.
To determine whether Dot1L deletion-induced bone marrow failure observed above is caused by autonomous defects of hematopoietic cells, we performed bone marrow transplantation in which the DOT1L 2lox/1ox /Cre-ER or DOT1L
wt/wt /Cre-ER donor cells were transplanted into congenic recipient mice (Supplementary information, Data S1). Four weeks after bone marrow reconstitution, TAM was administrated for 2 weeks to delete DOT1L in DOT1L 2lox/1ox /Cre-ER donor cells. Two weeks after the last TAM injection, total bone marrow cells were isolated and counted. Compared to mice transplanted with wildtype donor cells, total bone marrow cells in the recipient mice transplanted with DOT1L 2lox/1ox /Cre-ER cells are significantly reduced ( Figure 1F ). This result suggests planted into congenic mice. Four weeks after bone marrow reconstitution, TAM was administered for 2 weeks to deplete DOT1L in DOT1L 2lox/1ox /Cre-ER donor cells. The contribution of wild-type (Ly5.1+) and DOT1L-depleted donor cells (Ly5.2+) to different hematopoietic lineages was then monitored by the percent change of Ly5.1+/Ly5.2+ cells. This analysis demonstrated that after TAM-induced DOT1L depletion, the percentages of Ly5.2+ DOT1L 2lox/1ox /Cre-ER donor cells are significantly decreased in CMP, GMP, and MEP populations ( Figure 1G , Supplementary information, Figure S3 ). We also observed significant decrease in the percent contribution of DOT1L-depleted Ly5.2+ cells in LSK (Lin-/ Sca1+/cKit+) hematopoietic stem cells (HSCs) as well as long-term reconstituting HSCs (Lin-/Sca1+/cKit+/ CD150+/CD48-) population ( Figure 1H , Supplementary information, Figure S4) . Finally, the percentage of DOT1L-depleted Ly5.2+ donor cells was also decreased in terminally differentiated myeloid (Gr-1+/Mac-1+) and lymphoid (B220+/CD27+) populations ( Figure 1I-1L , Supplementary information, Figures S5 and S6) . Collectively, results from the bone marrow transplantation experiments support our conclusion that DOT1L is critical for maintaining normal adult hematopoiesis in mice.
In this study, we demonstrated that DOT1L plays an important role in maintaining normal adult hematopoiesis using conditional DOT1L-knockout mice coupled with bone marrow transplantation assay. Knockout of DOT1L in bone marrow cells depletes hematopoietic stem cells, various progenitor cell populations, as well as terminally differentiated blood cell lineages supporting a role for DOT1L in maintaining the hematopoietic progenitor and stem cell population. Using a similar approach, a recent study from the Hess group also reached the same conclusion [9] . Interestingly, DOT1L is also required for embryonic erythropoiesis [10] . Although the demonstration that DOT1L plays an important role in adult hematopoiesis raises concerns for targeting DOT1L for leukemia treatment, it does not exclude the possibility of using small molecule inhibitors that target DOT1L since it is possible that normal hematopoietic stem/progenitors and leukemic cells may have different sensitivities to DOT1L inhibition. Therefore, comparing the sensitivity of normal hematopoietic stem/progenitor cells with leukemia cells to potent DOT1L inhibitors will be important in determining the therapeutic window.
